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A B S T R A C T
Microglia, the primary regulators of inflammatory responses in the brain, suffer deterioration during aging
culminating in their inability to generate adequate adaptive responses to maintain physiological homeostasis in
brain tissue. Microglia affect the function of other glial cells and neurons, including those involved in the hy-
pothalamic control of body homeostasis. Microglial dysfunction with aging in cognitive areas such as the hip-
pocampus is known to associate with cognitive decline; more recently, microglial alterations in the hypotha-
lamus during midlife was suggested to participate in changes in the endocrine and metabolic control exerted by
this brain region. Consequently, the feed-back loops between endocrine glands and the hypothalamus are al-
tered. This generates a vicious circle in which the plasma levels of key neuroprotective hormones, such as
gonadal hormones, insulin-like growth factor-1, growth hormone and leptin and their hypothalamic signaling
are decreased, which further enhances microglial alterations and deterioration of hypothalamic function.
Hypothalamic dysfunction is a risk factor for neurodegenerative diseases and these diseases in turn promote
additional alterations in hypothalamic microglial cells, which are unable to cope with the neurodegenerative
process, resulting in permanent damage of the neuronal-glial circuits controlling endocrine homeostasis, food
intake and body metabolism. Thus, a “vicious cycle” may such be initiated.
1. Introduction
Health, wellbeing and homeostasis of the human body are highly
dependent on the correct functioning of the hypothalamus. This key
brain center exerts its homeostatic control through two parallel and
complementary mechanisms: 1) The release of hypothalamic neuro-
peptides that control the release of hormones that modify the activity of
peripheral endocrine glands. 2) The governance of hypothalamic and
extra-hypothalamic neuronal circuits involved in endocrine functions,
food intake and energy balance through the release of neuro-
transmitters and the modulation of neurotransmission. The activity of
hypothalamic neuronal circuits controlling body homeostasis is under
fine temporal tuning by peripheral hormones and vagal inputs that send
feed-back regulatory signals to the hypothalamus, assuring that hy-
pothalamic activity is adequately adjusted to body needs. The neuronal
circuits that regulate body homeostasis have been actively studied for
many years and our understanding of this central control has progres-
sively increased. It is assumed that defective functioning of these cir-
cuits underlies the decline in neuroendocrine systems associated with
aging and neurodegenerative conditions (Zhang et al., 2013). A major
question remains as to why these circuits become dysfunctional under
these circumstances. The answer may reside in a cellular component
that is emerging as a key player in the hypothalamic neuroendocrine
regulation: glial cells (Chowen et al., 2016; Douglass et al., 2017b;
Ojeda et al., 2008; Oliet et al., 2004).
In the mammalian brain, glial cells are classified as microglia and
macroglia (Fig. 1). Microglia, the macrophages of the brain, actively
and continuously sense for alterations in the homeostatic conditions of
brain tissue. They have phagocytic activity and are the primary reg-
ulators of local inflammatory responses in the neural parenchyma
(neuroinflammation) in response to disturbances in the cellular en-
vironment (Michell-Robinson et al., 2015). Macroglia are composed of
a variety of cell types, including astrocytes, oligodendrocytes and NG2
cells, a more recently recognized type of glial cell characterized by the
expression of NG2 proteoglycan (Hill and Nishiyama, 2014), as well as
specialized macroglia located in the cerebellum (Bergmann glia) and
the hypothalamus (tanycytes). This broad variety of glial cell types in
the mammalian brain is not found in invertebrates or lower vertebrates.
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Indeed, it appears that glial cells have experienced more morphological
and functional changes throughout phylogenetic evolution than neu-
rons. This must attest to their increasing importance throughout evo-
lution and in higher species.
Glial cells were originally considered to be mere elements of support
for neurons; however, we now know that they perform a wide spectrum
of actions that are essential in the regulation of brain function.
Astrocytes are sensitive to changes in neuronal activity through their
expression of receptors for neurotransmitters and neuromodulators and
they actively participate in the processing of information in the brain.
Indeed, they regulate neuronal communication by releasing glio-
transmitters, such as ATP, glutamate, GABA and D-serine. They also
form cellular syncytia connected by gap junctions that function to in-
tercommunicate the synaptic activity of distant neurons. Thus, in con-
junction with pre- and postsynaptic neuronal terminals, astrocyte pro-
cesses are now recognized as the third component of synapses (Papouin
et al., 2017; Perea et al., 2009).
Astrocytes also play a key role in brain function by providing fuel to
sustain neuronal function, adapting the energy supply to neuronal ac-
tivity (Belanger et al., 2011). Astrocytes and other macroglial cells,
such as tanycytes, transport glucose from the circulation, participate in
glucose-sensing mechanisms (Elizondo-Vega et al., 2015; Frayling et al.,
2011), accumulate energy deposits in the form of glycogen (Dringen
and Hamprecht, 1992) and sense neuronal activity in order to provide
lactate to neurons according to their metabolic needs (Belanger et al.,
2011). Astrocytes, together with tanycytes, endothelial cells and peri-
cytes, are an essential component of the blood-brain barrier and reg-
ulate the flux of molecules between the body and the brain (Cabezas
et al., 2014). Moreover, astrocyte end-feet surrounding brain capillaries
are fundamental in synchronizing neuronal metabolism with cerebral
blood flow (Petzold et al., 2008; Takano et al., 2006). In the hypotha-
lamus, morphological changes in astrocytes and tanycytes are
associated with modifications in the synaptic plasticity of neuronal
circuits involved in regulating the release of hormones, such as gona-
dotropin-releasing hormone (GnRH) and oxytocin (Chowen et al., 2016;
Oliet et al., 2008; Sharif et al., 2013). Astrocytes and tanycytes also
release factors that regulate the activity of hypothalamic neurons, in-
cluding transforming growth factor (TGF) α, TGFβ1, TGFβ2, fibroblast
growth factor (FGF), insulin-like growth factor-1 (IGF-1), vascular en-
dothelial growth factor A (VEGF-A), prostaglandins and progesterone
(Langlet et al., 2013; Prevot et al., 2003; Sinchak et al., 2003).
Hypothalamic glial cells are also involved in the control of food
intake and energy expenditure. Energy metabolism is primarily regu-
lated by two groups of neurons in the human hypothalamic in-
fundibular nucleus (arcuate nucleus in rodents): 1) Pro-opiomelano-
cortin (POMC) neurons that release α-melanocyte stimulating hormone
(α-MSH) to promote energy expenditure and inhibit feeding and 2)
Neuropeptide Y (NPY) neurons that release Agouti-related peptide
(AgRP) and NPY to stimulate feeding and decrease energy expenditure
(Koch and Horvath, 2014; Luquet et al., 2005). Both POMC and NPY
neurons are under the control of systemic feed-back signals including
the anorexigenic hormone leptin, produced mainly by adipocytes, and
the orexigenic hormone ghrelin produced in the stomach, with these
neurons projecting to and regulating other neuronal populations in-
volved in metabolic control. Astrocytes, microglia, NG2-glia and tany-
cytes participate in the hypothalamic sensing of metabolic hormones,
such as insulin and leptin (Djogo et al., 2016; Fuente-Martin et al.,
2012; Garcia-Caceres et al., 2016; Kim et al., 2014; Wang et al., 2015)
and other metabolic signals, such as glucose and fatty acids (Belanger
et al., 2011; Elizondo-Vega et al., 2015; Le Foll et al., 2014) (Fig. 1). For
instance, hypothalamic astrocytes express receptors for and respond to
metabolic hormones, including insulin, leptin, ghrelin, estradiol and
glucocorticoids (Chowen et al., 2016; Diano et al., 1998a; Douglass
et al., 2017b; Fuente-Martin et al., 2016; Garcia-Caceres et al., 2016;
Fig. 1. Role of hypothalamic glial cells in neuroendocrine control. Tanycytes, microglia, astrocytes and NG2 cells participate in the sensing of endocrine and
metabolic signals and regulate the function and activity of the hypothalamic neuroendocrine neuronal circuits.
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Hsuchou et al., 2009). Expression of leptin receptors in astrocytes and
NG2 cells is necessary for the correct actions of leptin on metabolic
circuits in the hypothalamus (Djogo et al., 2016; Kim et al., 2014; Wang
et al., 2015). The genetically induced lack of leptin receptors in glial
fibrillary acidic protein (GFAP) positive astrocytes modifies the mor-
phological interaction of the cellular processes of these glial cells with
the surface of POMC and AgRP neuronal somas. This is associated with
alteration of the number of synaptic inputs to these neurons, as well as
the balance between stimulatory and inhibitory inputs, and thus mod-
ifications in their activity (Kim et al., 2014). Leptin also controls the
transport of glucose and glutamate by astrocytes, affecting their reg-
ulation of neuronal metabolism (Fuente-Martin et al., 2012). Moreover,
astrocytes are fundamental in mediating the effects of insulin on neu-
ronal metabolism throughout the brain and in the hypothalamus this
affects systemic energy homeostasis (Fernandez et al., 2017; Garcia-
Caceres et al., 2016).
Tanycytes, which sense, transport and respond to metabolic signals
such as glucose, leptin, IGF-1 and estradiol, also metabolize thyroxine
(T4) to triiodothyronine (T3) and are therefore important mediators of
the actions of thyroid hormone in the hypothalamus (Balland et al.,
2014; Diano et al., 1998b; Elizondo-Vega et al., 2015; Frayling et al.,
2011; Langlet et al., 2013). Glia, and in particular tanycytes, are a
source of neuroprogenitor cells (Chaker et al., 2016; Lee et al., 2012),
allowing the renovation of hypothalamic neuroendocrine and meta-
bolic circuits and their continual adjustment to the nutritional/hor-
monal environment (Lee et al., 2012; McNay et al., 2012).
The surge of publications in the past decade analyzing glial cells in
metabolic homeostatic control is due, at least in part, to the demon-
stration that in high fat diet (HFD)-induced obese rodents inflammatory
processes in the hypothalamus are directly involved in central insulin
resistance and disruption of systemic glucose homeostasis (De Souza
et al., 2005) and that hypothalamic inflammation has also been ob-
served in humans with obesity (Thaler et al., 2012). Microglia have
been closely linked to the obesity-induced inflammation in the hy-
pothalamus, with these glial cells shown to respond to both hormonal
and nutrient signals to initiate inflammatory signaling (Gao et al., 2014;
Milanski et al., 2009; Valdearcos et al., 2014). Depletion of microglia in
the medial basal hypothalamus or inhibition of inflammatory signaling
cascades specifically in microglia improves the metabolic profile in
obese subjects with insulin resistance (Andre et al., 2017; Valdearcos
et al., 2017, 2014), with a similar observation being reported in as-
trocytes (Buckman et al., 2015; Douglass et al., 2017a). However, the
process of astrogliosis is biphasic (Thaler et al., 2012), with a rapid
initial phase interpreted as protective and involved in the physiological
adaptation to increased energy intake (Buckman et al., 2015), while
delayed prolonged astrogliosis participates in the detrimental response
to obesity/poor nutrition, including secondary complications and per-
petuation of increased weight gain (Douglass et al., 2017a).
As will be seen in the following sections, we propose that under-
standing the role of glial cells in neuroendocrine and metabolic control
is key for delineating how hypothalamic dysfunction participates in
aging and neurodegeneration, as well as how poor nutrition and obesity
influence these processes and the mechanisms involved. Indeed, both
aging and neurodegeneration are characterized by alterations in glial
cell function and this occurs in parallel with enhanced neuroin-
flammation in the hypothalamus.
2. Age-associated hypothalamic dysfunction during midlife is
linked to microglial alterations
2.1. Aging of endocrine systems
Throughout life there is continuous crosstalk between the endocrine
glands and the hypothalamus to control and adjust physiological pro-
cesses to maintain homeostasis. This occurs through specific feed-back
loops that must be under constant adjustment in order to adapt to
changes in the environment. There are certain physiological periods
and events in the life of an individual when these adjustments are quite
complex, such as during early development, puberty, reproductive cy-
cles, pregnancy, parturition, the early postpartum period and lactation
(García-Segura, 2009). The feed-back loops between the hypothalamus
and endocrine glands also undergo striking reorganization during aging
and under pathological conditions (García-Segura, 2009). The aging
process is gradual, but with clear alterations in endocrine gland and
hypothalamic function becoming apparent around midlife and this is
associated with a decline in the levels of many circulating hormones
(Lamberts et al., 1997). Since the hypothalamus controls the activity of
the endocrine glands and the hormones produced by these glands feed-
back to regulate hypothalamic function, it has been difficult to de-
termine whether the midlife-appearance of endocrine dysfunction in-
itiates in the hypothalamus or if it is triggered by alterations in per-
ipheral hormone levels. One likely scenario is that during aging there is
continuous and progressive remodeling of the feed-back loops in order
to maintain the coordinated actions of the hypothalamus and endocrine
glands, but this eventually culminates in a catastrophic point at which
these regulatory feed-back loops cannot be sufficiently adjusted to
maintain systemic homeostasis. They thus become permanently im-
paired, accelerating and perpetuating the decline in hypothalamic
function.
2.2. Microglia senescence
Brain aging is associated with microglial senescence, which results
in increased gliosis and neuroinflammation (Cornejo and von
Bernhardi, 2016; Matt and Johnson, 2016). It should be made clear that
senescent microglia do not have the same phenotype as microglia that
have been activated in response to acute brain injury or infection.
Young reactive microglia exert neuroprotective actions to promote
tissue repair and the recovery of tissue homeostasis. In contrast, se-
nescent microglia are dysfunctional cells that are unable to properly
react to brain alterations (Fig. 2). Senescent microglia exhibit increased
basal phagocytic activity, but their induced phagocytic activity is im-
paired. Their dendritic arborization is decreased, as is their motility and
capacity to shift from a proinflammatory to an anti-inflammatory
phenotype (Cornejo and von Bernhardi, 2016; Matt and Johnson,
2016). These changes in aged microglia have an important impact on
brain function. The decreased dendritic arborization and motility of
aged microglia reduces their surveying capacity and their ability to
react to harmful stimuli, which in turn hinders their effectiveness in
adequately maintaining homeostasis in brain tissue. Furthermore, mi-
croglial phagocytic activity is essential for synaptic plasticity and adult
neurogenesis to occur correctly (Schafer et al., 2012; Sierra et al., 2010)
and, as senescent microglia are incapable of adequately adapting pha-
gocytosis to homeostatic needs, these functions are compromised in the
aging brain. Senescent microglia are also unable to adjust their transi-
tion between pro-inflammatory and anti-inflammatory activity to meet
homeostatic needs resulting in the inadequate release of proin-
flammatory cytokines, such as interleukin (IL) -1β, IL-6 and tumor
necrosis factor (TNF)-α. This promotes chronic neuroinflammation and
alters the function of other brain cell types, including astrocytes and
neurons (Cornejo and von Bernhardi, 2016; Matt and Johnson, 2016;
Zhang et al., 2013). Alteration of these cell types in the hypothalamus
would directly affect neuroendocrine and endocrine function, including
metabolic control.
2.3. Hypothalamic inflammation and aging
It has been suggested that, at least in mice, aging of the hypotha-
lamus is the cause of systemic aging (Zhang et al., 2013). Although the
existence of senescent microglia has not been demonstrated in the hy-
pothalamus, microglial cells in this brain region progressively acquire a
dysfunctional proinflammatory phenotype during the aging process
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that is characterized by elevated nuclear factor κ – light chain – en-
hancer of activated B cells (NFκB) signaling (Zhang et al., 2013). The
inappropriate activation of NFκB in hypothalamic microglia and the
resulting increased expression and release of pro-inflammatory cyto-
kines, such as TNF-α, activates NFκB in neurons (Zhang et al., 2013).
This proinflammatory condition is associated with increased expression
of TGFβ in astrocytes, which results in further hypothalamic NFκB ac-
tivation (Yan et al., 2014). Therefore, in the aged hypothalamus, as-
trocytes acquire a reactive phenotype that involves changes in cell
morphology and the release of glial factors that alter neuron-glia
crosstalk (Kaur et al., 2008; Yan et al., 2014). Since astrocytes regulate
the actions of peripheral hormones on hypothalamic neurons, the al-
teration in their function, as a consequence of the local uncontrolled
neuroinflammatory environment, will in turn affect the hypothalamic
regulation of body homeostasis. Indeed, not only are the circuits con-
trolling systemic metabolism altered, resulting in an increased pro-
pensity to gain weight and develop diseases such as diabetes mellitus
type 2, but inflammatory processes in the hypothalamus of aged mice
result in the down-regulation of GnRH expression, which contributes to
systemic aging (Zhang et al., 2013). These findings in mice suggest that
age-associated microglial alterations in the hypothalamus, and the
consequent over-activity of NFκB signaling in microglia and astrocytes,
is involved in systemic aging.
Deregulation of the hypothalamic neuroinflammatory response
during aging results in modifications in the control of neuroendocrine
axes that in turn amplify the process of hypothalamic aging (Garcia-San
Frutos et al., 2012; Yan et al., 2014; Zhang et al., 2013) (Fig. 3). For
instance, the down-regulation of GnRH secretion by hypothalamic in-
flammation (Morelli et al., 2014; Zhang et al., 2013) affects the hy-
pothalamic control of gonadal hormone synthesis. In mammals, go-
nadal hormones are essential signals for the modification and
reorganization of neurons, glial cells and their interactions that occur in
the hypothalamus and other brain regions during critical periods of life
such as prenatal development, puberty, reproductive cycles, pregnancy,
motherhood, menopause and aging (García-Segura, 2009). Plasma le-
vels of gonadal hormones, as well as their precursor dehydroepian-
drosterone (DHEA), decrease in both men and women during midlife
(Lamberts et al., 1997). These hormones exert neuroprotective actions
and reduce the activation of astrocytes and microglia, thus decreasing
gliosis and neuroinflammation (Acaz-Fonseca et al., 2016). Hence, it is
plausible that the decline in gonadal hormone levels during midlife in
men and women is one of the main phenomena promoting hypotha-
lamic aging. The age-associated decrease in gonadal hormones is ac-
companied by reduced levels of growth hormone (GH), which in turn
results in decreased serum levels of IGF-1 (Lamberts et al., 1997), a
component of the GH axis, whose expression and signaling in different
tissues, including the brain, is regulated by estradiol (Cardona-Gomez
et al., 2002; Munive et al., 2016; Perianes-Cachero et al., 2015;
Sohrabji, 2015). IGF-1 is a neuroprotective factor that promotes neuron
survival and adult neurogenesis, including hypothalamic neurogenesis
Fig. 2. Characteristics of senescent microglia. Representation of the differences between quiescent, activated and senescent microglia. In contrast to young
activated microglia, senescent microglia are unable to mount an adequate homeostatic inflammatory response.
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(Chaker et al., 2016; Perez-Martin et al., 2010), and reduces gliosis and
neuroinflammation, down-regulating NFκB activity (Bellini et al.,
2011). Although the brain also produces IGF-1, circulating IGF-1 has
been shown to directly affect brain function (Carro et al., 2005; Trejo
et al., 2007); thus, the midlife decline in circulating levels of this hor-
mone could further enhance hypothalamic aging. In addition, the IGF-1
receptor interacts with estrogen receptor alpha in the hypothalamus to
activate neuroprotective and anti-inflammatory signaling mechanisms
(Mendez et al., 2003) and the age associated decline in the levels of
gonadal hormones and IGF-1 could impair this interaction. This is not
only pertinent regarding the decrease in circulating estradiol levels in
midlife women, as in fact, peripheral testosterone is converted to es-
tradiol within the human male and female brain. Therefore, the age-
associated decline in plasma testosterone levels in men and the age-
associated decrease in plasma levels of estradiol in women, together
with the decrease in plasma IGF-1 levels in both sexes (Lamberts et al.,
1997), reduces the coordinated neuroprotective and anti-inflammatory
signaling of estrogen receptor alpha and the IGF-1 receptor in the brain,
resulting in enhanced hypothalamic gliosis and neuroinflammation.
Thus, the parallel decline in the activity of the GH and gonadal hor-
mone axes may be one of the main events initiating generalized hy-
pothalamic dysfunction with aging. The physiological differences be-
tween the sexes, especially regarding the reproductive axis and steroid
hormone production, varyingly affect this aging process and the asso-
ciated peripheral outcomes. Indeed, females tend to be less susceptible
to metabolic alterations, at least before menopause (Palmer and Clegg,
2015).
3. Microglia are involved in the alteration of neuroendocrine
control at midlife, which further exacerbates hypothalamic
dysfunction
3.1. Aging, dietary habits and hypothalamic inflammation
The age-associated increase in hypothalamic inflammation causes
impaired hypothalamic sensing of metabolic hormones and the in-
adequate regulation of energy expenditure, which in turn promotes
increased adiposity in men and women during midlife. These metabolic
Fig. 3. Vicious circle of aging-associated hypothalamic neuroinflammation and loss of metabolic control. Microglia at midlife causes hypothalamic in-
flammation and the impaired function of hypothalamic neuroglial regulation of metabolic control. This causes metabolic alterations that are exacerbated by poor
dietary habits, which promote hypothalamic microglia activation and further hypothalamic inflammation, enhancing the loss of neuroendocrine and metabolic
control.
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alterations caused by hypothalamic aging can be exacerbated by life-
style factors, such as diets rich in fat and sugar and sedentary behavior,
which enhance hypothalamic inflammation (Milanski et al., 2009;
Thaler et al., 2012) and impair hypothalamic control of metabolic
function; this can result in obesity and metabolic syndrome (Fig. 4). In
addition, obesity associated hypothalamic inflammation impairs GnRH
secretion (Morelli et al., 2014), which as previously stated contributes
to systemic aging (Zhang et al., 2013).
Peripheral metabolic alterations associated with obesity and poor
dietary habits, such as high levels of dietary saturated fatty acids, ac-
tivate NFκB signaling in mediobasal hypothalamic microglia, pro-
moting autophagy, endoplasmic reticulum stress and oxidative stress,
resulting in hypothalamic insulin, ghrelin and leptin resistance and
further promoting hypothalamic neuroinflammation and dysfunction
(Kleinridders et al., 2009; Milanski et al., 2009; Valdearcos et al., 2014;
Zhang et al., 2008). High fat diet intake stimulates neurogenesis in the
hypothalamus, with this increase in cell turnover thought to be bene-
ficial by promoting metabolic adaption to dietary changes (Lee et al.,
2012; McNay et al., 2012). However, hypothalamic neurogenesis and
the generation of neurons involved in metabolic control decrease with
age (Chaker et al., 2016; McNay et al., 2012), which reduces this
adaptive capacity and results in increased weight gain in response to
dietary challenges. This decrease in proliferative capacity may be at
least partially due to the age associated increase in local inflammatory
processes initiated by microglia and the impaired neurogenesis-asso-
ciated phagocytic function of microglia, in conjunction with the decline
in hypothalamic neurogenesis promoting hormones such as IGF-1 and
estrogens (Chaker et al., 2016; Lamberts et al., 1997; Sierra et al.,
2010).
3.2. Microglia, diet and hypothalamic inflammation
The deletion or silencing of microglia in the mediobasal hypotha-
lamus of rodents prevents saturated fatty acid-induced hypothalamic
neuroinflammation and high fat diet - induced weight gain (Andre
et al., 2017; Valdearcos et al., 2017, 2014). Thus, we could propose the
following scenario: saturated fatty acids from the acute ingestion of a
high fat diet induce the transient release of proinflammatory molecules
by microglia, initially as an adaptive response to maintain metabolic
control (Thaler et al., 2012). However, if the high fat diet is prolonged,
the adaptive response of microglia is impaired, resulting in chronic
neuroinflammation and hormonal changes that perpetuate weight gain
and neuroinflammation (Gao et al., 2014; Thaler et al., 2012). Similar
to microglia during aging, diet-induced reactive microglia would acti-
vate astrocytes, altering their morphology and their contacts with
neurons and brain capillaries (Horvath et al., 2010). This alteration of
astrocytes, and possibly tanycytes, would affect the transport of leptin
and other metabolic signals through the blood-brain barrier (Balland
et al., 2014; Fuente-Martin et al., 2016, 2012), promoting decreased
hypothalamic leptin sensing and impaired insulin signaling. Central
insulin and leptin resistance impair the correct functioning of hy-
pothalamic circuits controlling food intake and metabolism (Halaas
et al., 1997; Sears and Perry, 2015), further promoting obesity and
resulting in a vicious circle. Thus, obesity and aging trigger similar
pathophysiological mechanisms associated with increased hypotha-
lamic microglia dysfunction and deregulated neuroinflammatory con-
trol.
3.3. Aging, microglia and metabolism
Age-associated impairment of the hypothalamic control of systemic
metabolism can result in obesity during midlife, but prolonged hy-
pothalamic microglial dysfunction, which is enhanced by obesity, is
associated with anorexia at older ages (Fig. 3). During midlife, in-
creased body weight is, at least in part, the consequence of obesity-
associated leptin and insulin resistance (Kleinridders et al., 2009;
Purkayastha et al., 2011; Spielman et al., 2014) and the impaired
functioning of NPY neurons caused by inflammation and deregulated
microglial activation (Dalvi et al., 2017). Permanent microglial acti-
vation could in addition contribute to both the age-associated death of
hypothalamic neurons (Leite et al., 2016) and the age-associated de-
crease in hypothalamic neurogenesis, which is then unable to replace
the damaged neurons. This would cause enhanced and progressive
functional impairment of hypothalamic circuits in elderly people, in-
cluding those circuits involved in metabolic control. Moreover, at older
ages the effect of ghrelin resistance in AgRP/NPY neurons predominates
(Briggs et al., 2014; Miyazaki et al., 2014), and together with the sti-
mulation of POMC neurons by hypothalamic cytokines (Jang et al.,
2010; Shi et al., 2013) increased energy expenditure and decreased
appetite would be favored. Aging is associated with a decline in plasma
ghrelin levels and a decrease in the acylated (active)/desacylated
ghrelin ratio in humans, which is thought to be involved in the de-
creased appetite observed in the elderly (Nass et al., 2014; Rigamonti
et al., 2002). The decrease in hypothalamic ghrelin signaling further
contributes to increased microglia activation (Fujitsuka et al., 2016),
enhancing hypothalamic neuroinflammation and the deterioration of
hypothalamic metabolic control. Therefore, in addition to the altera-
tions in ghrelin signaling in hypothalamic AgRP/NPY neurons with
aging, microglial activation and cytokine production in the hypotha-
lamus can contribute to weight loss in the elderly or cachexia in disease
by stimulating POMC neurons (Jang et al., 2010; Shi et al., 2013).
Ghrelin also regulates systemic metabolism by acting on
Fig. 4. Role of microglia on the loss of neu-
roendocrine control by the hypothalamus.
Impaired function of microglia in the aged
brain results in aberrant NFκB activation in the
hypothalamus, affecting the function of neu-
rons and other glial cells. This results in loss of
neuroendocrine and metabolic control. The
consequent decrease in the levels of neuropro-
tective hormones, such as IGF-1 and estradiol,
further exacerbates hypothalamic dysfunction.
Neurodegenerative diseases affect the hy-
pothalamus and further enhance endocrine and
metabolic alterations.
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extrahypothalamic regions, such as the ventral tegmental area and ac-
tions of ghrelin on the dopaminergic neurons of this brain region are
involved in the regulation of reward and motivation (Stievenard et al.,
2017). Thus, altered ghrelin signaling in the aged brain could also alter
motivation for food, contributing to weight loss and physical frailty in
elderly individuals and in patients with neurodegenerative diseases.
Aging in humans is characterized by elevated plasma levels of in-
terleukin (IL)-1β, IL-6, TNFα and leukemia inhibitory factor (LIF)
(Gameiro et al., 2010; Maggio et al., 2005). These cytokines reach the
brain where they stimulate the inflammatory response of hypothalamic
microglia. Under neuroinflammatory conditions, glial cells in the hy-
pothalamic arcuate nucleus of rodents modify their physical interaction
with the surface of POMC neurons, changing the ratio of excitatory and
inhibitory synaptic inputs on these neurons and increasing their activity
(Horvath et al., 2010). In addition, the activation of NFκB promotes
POMC transcription (Jang et al., 2010; Shi et al., 2013). The increased
activity of POMC neurons then results in anorexia, which can be re-
versed with antagonists of NFκB (Jin et al., 2016). Moreover, studies of
genetically modified rodents have shown that hypothalamic IL-1β and
LIF stimulate the production of α-MSH through a mechanism involving
NFκB activation in POMC neurons (Grossberg et al., 2010). This sce-
nario would result in suppression of food intake and enhanced energy
expenditure.
Physical frailty is a predictor for the development of aging-asso-
ciated neurodegenerative diseases and aging is a risk factor for the
development of Alzheimer’s, Parkinson’s and Huntington’s diseases
(Buchman et al., 2005; James et al., 2014; Liot et al., 2017). As men-
tioned before, during aging microglia become less neuroprotective, less
effective in maintaining neuronal homeostasis and less capable of
counteracting neurodegenerative alterations than young microglia
(Cornejo and von Bernhardi, 2016; Cho et al., 2015; Matt and Johnson,
2016). As ghrelin, leptin, insulin, gonadal hormones and IGF-1 are
neuroprotective factors and exert anti-inflammatory actions, the aging-
associated decrease in their plasma levels and the increased leptin, in-
sulin and IGF-1 resistance could contribute to the onset and propaga-
tion of the pathological alterations in the brain of patients with neu-
rodegeneration. Obesity during midlife has also been linked to the
development of age-associated neurodegenerative diseases (Procaccini
et al., 2016; Spielman et al., 2014). This is probably due, at least in part,
to the obesity-induced resistance to neuroprotective hormones, such as
insulin, IGF-1 and leptin, and the obesity-associated activation of hy-
pothalamic inflammatory mechanisms (Spielman et al., 2014). There-
fore, hypothalamic microglial dysfunction in midlife and the con-
sequent alteration in neuroendocrine control may represent a risk factor
for the development of aging-associated neurodegeneration, with poor
dietary intake and obesity possibly accelerating this process.
4. Neurodegenerative diseases accelerate hypothalamic
dysfunction and loss of neuroendocrine control
4.1. Neurodegenerative diseases and hypothalamic alteration
It has been proposed that the aging-associated loss of neuroprotec-
tive properties of microglia precedes and participates in the onset of
neurodegenerative alterations (Streit et al., 2009). Dysfunctional mi-
croglia in the aged brain would also contribute to the amplification of
the pathological alterations that occur during the course of the disease.
In turn, neurodegenerative alterations further impair microglia function
(Davies et al., 2016). Aging-associated neurodegenerative diseases are
usually diagnosed due to their motor and/or cognitive symptoms;
however, these neurodegenerative diseases also affect systemic home-
ostasis. Although most studies on the pathological alterations in the
brain of Alzheimer’s patients have focused on cognitive brain regions
such as the cerebral cortex and the hippocampus, the hypothalamus is
also affected by this disease. Loss of specific hypothalamic neuronal
populations and modifications in their dendritic arbors, dendritic spines
and axons have been described in patients with Alzheimer’s disease and
in animal models of this disease (Baloyannis et al., 2015). β-amyloid
plaques and neurofibrillary tangles are also detected in the hypotha-
lamus of Alzheimer’s disease patients (Airaksinen et al., 1991) and
neuroimaging techniques have revealed hypothalamic atrophy and re-
duced hypothalamic glucose metabolism in this neurodegenerative
disease (Ishii and Iadecola, 2015).
Decreased hypothalamic volume is also detected in Parkinson’s
disease patients (Breen et al., 2016), together with loss of hypothalamic
oxytocin, dopaminergic and orexin neurons (Fronczek et al., 2007;
Politis et al., 2008b; Purba et al., 1994; Thannickal et al., 2007). Nu-
clear inclusion bodies with mutated huntingtin, hypothalamic atrophy
and loss of specific neuropeptidergic neuronal populations, such as
oxytocin, vasopressin, orexin and NPY neurons, are detected in the
hypothalamus of Huntington’s disease patients (Aziz et al., 2008a;
Gabery et al., 2010; Kremer et al., 1990; Petersen et al., 2005; Soneson
et al., 2010; van Wamelen et al., 2013).
Pathological alterations of the hypothalamus in neurodegenerative
diseases are associated with modifications in the hypothalamic control
of neuroendocrine function. Indeed, modifications in plasma levels of
different hormones are detected in patients with neurodegenerative
diseases. For instance, male patients with Parkinson’s disease have in-
creased prolactin levels and decreased gonadal hormone levels com-
pared to aged-matched control subjects (Nitkowska et al., 2015); LH
levels are increased and free testosterone levels are decreased in male
patients with Alzheimer’s disease (Butchart et al., 2013), while in male
patients with Huntington’s disease lower testosterone and LH levels
compared to aged-matched controls have been reported (Markianos
et al., 2005). Furthermore, GH, ghrelin and prolactin levels are in-
creased and IGF-1 and leptin levels are decreased in Huntington’s dis-
ease patients of both sexes (Mochel et al., 2007; Popovic et al., 2004;
Wang et al., 2014). High basal cortisol levels and insensitivity to glu-
cocorticoid feedback are also observed in Alzheimer’s patients, in-
dicating impairment of hypothalamic –pituitary–adrenal axis function
(Hatzinger et al., 1995; Huang et al., 2009). Hypothalamic modifica-
tions in Alzheimer’s disease have also been associated with the in-
creased bone loss observed in these patients (Loskutova et al., 2019).
These endocrine alterations are indicative of a disruption in the cross-
talk between the hypothalamus and the endocrine glands.
Another common characteristic of patients with advanced
Alzheimer’s, Parkinson’s or Huntington’s disease is a dramatic loss of
body weight (Aziz et al., 2008b, c). This is most likely the consequence
of the pathological changes in the hypothalamus of these patients. In
particular, hypothalamic microglia dysfunction in these pathologies
(Bisht et al., 2016; Bryan et al., 2008; Politis et al., 2008a) may con-
tribute to accelerate the aging-associated loss of hypothalamic meta-
bolic control by modifying the ability of astrocytes and tanycytes to
sense and transport metabolic hormones and by altering the function of
the blood brain barrier, which is affected in neurodegenerative diseases
(Chakraborty et al., 2017). In addition, the impaired neuroprotective
function of microglia in neurodegenerative diseases in the aged brain
(Cornejo and von Bernhardi, 2016) could contribute to the loss of hy-
pothalamic neurons involved in metabolic control, such as orexin and
NPY neurons (Fronczek et al., 2007; Gabery et al., 2010; Petersen et al.,
2005; Thannickal et al., 2007; van Wamelen et al., 2013).
4.2. Neuroprotective hormones, aging and neurodegenerative diseases
Changes in cognitive function during aging have been associated
with modifications in circulating levels of neuroprotective hormones,
although some conclusions are controversial. Paulsen and colleagues
analyzed approximately 2000 aging subjects with no cognitive im-
pairment at baseline to determine their 5-year risk of impaired cogni-
tive function or dementia (Paulsen et al., 2019). They report that in
men risk of developing cognitive impairment was decreased with in-
creased IGF-1 levels, while in both men and women low levels of BDNF
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were associated with increased risk of cognitive function impairment at
5 years.
Circulating IGF-1 levels in patients with Alzheimer’s disease have
been reported to be increased, decreased or unchanged with meta-
analysis of 9 different studies indicating that no direct relationship
between IGF-1 levels and Alzheimer’s disease can be drawn (Ostrowski
et al., 2016). However, as many factors must be taken into considera-
tion, such as age, nutritional status, etc, the control population used for
comparison is clearly important. Moreover, most studies have analyzed
total circulating IGF-1 levels, while free or bioactive IGF-1 levels may
be a more appropriate measurement to determine relationships with
disease processes. Indeed, free IGF-1 is reported to be reduced in serum
of subjects with Alzheimer's disease (Alvarez et al., 2007), with this
decrease shown to be positively correlated with a significant increase in
circulating TNF-α levels (Alvarez et al., 2007).
Free testosterone levels have been associated with amyloid-B levels,
as well as neurodegeneration in the hippocampus, in subjects with
impaired cognition, with levels of this sex steroid being positively
correlated with hippocampal volume in males and inversely related
with amyloid-B levels in females (Lee et al., 2017). As mentioned
above, free testosterone levels are decreased in male patients with
Alzheimer’s disease (Butchart et al., 2013), as well as with Huntington’s
disease (Markianos et al., 2005).
In women, the incidence of Alzheimer’s disease is reported to in-
crease during the postmenopausal period due to the decline in neuro-
protective estrogen’s (Depypere et al., 2016). However, estrogen
treatment of postmenopausal women to decreased dementia/Alzhei-
mer’s remains controversial (Depypere et al., 2016). Estrogen treatment
of recently postmenopausal women is reported to decrease amyloid-β
deposition (Kantarci et al., 2016). In a nationwide case control study,
postmenopausal hormone replacement was not found to be a determi-
nant of risk for Alzheimer’s disease (Imtiaz et al., 2017). In addition, in
a recent study analyzing over 84,000 women diagnosed with Alzhei-
mer’s disease the long-term use of systemic steroid replacement was
associated with an increased risk for this disease (Savolainen-Peltonen
et al., 2019). Thus, although the lack of estrogens appears to be clearly
associated with cognitive deterioration, there is no evident effect of
hormonal replacement on development of Alzheimer’s disease. Hor-
monal therapy is generally instituted once the endocrine effects of aging
are apparent. As the aging process is gradual, it is possibly too late to
interrupt the vicious cycle of deterioration of the endocrine axes, mi-
croglial dysfunction and neurodegeneration.
4.3. Alzheimer´s disease, microglia and metabolic hormones
Changes in the hypothalamic signaling of neuroprotective hor-
mones, which also regulate the inflammatory responses of microglia
and astrocytes, will further accelerate hypothalamic dysfunction in
neurodegenerative diseases. For instance, plasma leptin levels, adjusted
for body weight, are reduced in Alzheimer’s disease patients and in
patients with age-associated dementia (Johnston et al., 2014; Witte
et al., 2016). In addition, leptin transport through the blood brain
barrier is impaired in animal models of Alzheimer’s disease (Dietrich
et al., 2008). Leptin exerts neuroprotective actions, stimulating the
phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin
(mTOR) and the Janus kinase (JAK)/signal transducer and activator of
transcription (STAT) signaling pathways, decreasing neuroinflamma-
tion, β-amyloid levels and Tau hyperphosphorylation and preventing
neuronal loss (Marwarha et al., 2014). Therefore, decreased leptin
signaling may contribute to hippocampal and hypothalamic neurode-
generation in Alzheimer’s disease.
Other relevant metabolic hormones in Alzheimer’s disease are in-
sulin and IGF-1. There is evidence that insulin resistance and the de-
regulation of glucose metabolism may contribute to enhance
Alzheimer’s pathology in humans (Arrieta-Cruz and Gutierrez-Juarez,
2016). Insulin signaling is decreased in the hypothalamus of mouse
models of Alzheimer’s disease (Ruiz et al., 2016). IGF-1 transport to the
brain is also decreased in Alzheimer’s disease patients and in animal
models of this disease (Trueba-Saiz et al., 2013). Impaired insulin and
IGF-1 signaling in Alzheimer’s disease may contribute to hypothalamic
dysfunction, since both hormones activate the PI3K/Akt neuroprotec-
tive signaling pathway, which inhibits glycogen synthase kinase β
(GSK3β) and reduces Tau phosphorylation and Alzheimer’s pathology.
In turn, Alzheimer’s pathology in the hypothalamus increases NFκB
activation (Clarke et al., 2015), which would contribute to POMC
neuronal dysfunction, further promoting suppression of food intake and
enhanced energy expenditure. Therefore, neurodegenerative diseases
accelerate aging-associated hypothalamic dysfunction, resulting in an
accelerated loss of neuroendocrine control.
4.4. Parkinson’s disease, microglia and metabolism
The role of glial cells in Parkinson’s disease has received increasing
attention in the past decade and has been recently reviewed (Tremblay
et al., 2019). One of the primary features of this neurodegenerative
disease is the accumulation of proteins resulting in cell stress and
eventually neuronal loss. When damaged cells are not removed the
system becomes further stress, augmenting and spreading tissue da-
mage. Although glial cells respond to local insults by producing cyto-
kines and other factors, they are also fundamental for phagocytosis and
synaptic pruning. Thus, impairment of the ability of glial cells, and
particularly of microglia, to adequately remove damaged cells and
debris increases neuronal stress and neuronal death.
The impairment of microglial function with aging and their reduced
ability to clear away damaged cells could contribute to augment the
susceptibility for neuronal loss in Parkinson’s disease. Mediterranean
diet, and particularly the increased intake of antioxidant phenols, is
suggested to protect against the development of neurodegenerative
diseases (Hornedo-Ortega et al., 2018). These dietary antioxidant ef-
fects could be executed directly at the level of the central nervous
system, but also through improvement in systemic metabolism, as has
been shown to occur with adherence to a Mediterranean diet (Estruch
et al., 2018). Thus, once again, a general improvement in dietary habits
and metabolic function can improve microglial function, decrease
neuroinflammation and have beneficial effects against neurodegenera-
tive diseases (Estruch et al., 2018; Hornedo-Ortega et al., 2018;
Johnson et al., 2019).
5. Conclusions and perspectives for the future
In this review we have focused on the role of microglia in the in-
itiation and propagation of hypothalamic dysfunction during aging and
in age-associated neurodegenerative diseases (Fig. 4). A key molecule in
this process is NFκB. The uncontrolled activation of NFκB signaling by
microglia, and the resulting alterations in other glial cell types and
neurons, impairs hypothalamic regulation of hormonal secretion, as
well as the hypothalamic ability to sense and respond to the hormonal
feed-back received from the endocrine glands. This creates a vicious
circle in which the aging-associated decrease in anti-inflammatory and
neuroprotective hormone levels and their hypothalamic signaling fur-
ther impairs microglia and hypothalamic function, generating a cascade
of events resulting in the inability of this brain center to properly
control body homeostasis. This vicious circle is exacerbated under the
course of neurodegenerative diseases, which affect hypothalamic
function. Further studies are necessary to determine the consequences
of impaired hypothalamic neuroendocrine control on the course of
neurodegenerative diseases and its impact on cognitive and motor
function, as well as possible mitigation of the aging and neurodegen-
erative processes by improved dietary habits. Moreover, neuroendo-
crine systems, particularly those involved in reproduction, differ be-
tween males and females, resulting in an aging process that is sex
specific. This fact most likely underlies sex differences in the propensity
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towards some neurodegenerative diseases during aging, as well as the
susceptibility to metabolic disorders and the perpetuation of the vicious
cycle of aging and indicates that studies aimed at developing effective
treatments for these conditions must take sex differences into account.
Although we have focused on age-associated neurodegenerative dis-
eases in this review, it will be important to investigate the role of hy-
pothalamic dysfunction in other neurodegenerative diseases that are
accompanied by a marked loss of neuroendocrine and metabolic con-
trol, such as amyotrophic lateral sclerosis. Finally, future studies should
also explore potential therapeutic interventions aimed to improve the
function of microglia and to control NFκB signaling in order to prevent
or counteract the decline in neuroendocrine control with aging and
disease.
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